The actual benefit is substantial in the second-line treatment of ALK+ advanced non-small cell lung cancer (NSCLC).
Clinical Added Value
moderate
XALKORI provides a moderate improvement in actual benefit (level III) in the treatment strategy of ALK+ advanced non-small cell lung cancer as a second-line therapy and compared with docetaxel or pemetrexed.
Listen
